Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 7.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 526,045 shares of the company’s stock after selling 43,140 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Fulcrum Therapeutics were worth $2,472,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in FULC. Bailard Inc. acquired a new stake in Fulcrum Therapeutics in the fourth quarter valued at $169,000. Bank of New York Mellon Corp lifted its stake in shares of Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock valued at $667,000 after purchasing an additional 3,126 shares in the last quarter. Matisse Capital lifted its holdings in shares of Fulcrum Therapeutics by 20.4% during the 4th quarter. Matisse Capital now owns 128,445 shares of the company’s stock valued at $604,000 after acquiring an additional 21,728 shares in the last quarter. Barclays PLC grew its holdings in Fulcrum Therapeutics by 367.1% during the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after purchasing an additional 97,565 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Fulcrum Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after buying an additional 13,485 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock opened at $3.01 on Friday. Fulcrum Therapeutics, Inc. has a 1 year low of $2.78 and a 1 year high of $10.13. The firm’s 50 day moving average price is $3.53 and its two-hundred day moving average price is $3.76. The firm has a market cap of $162.48 million, a price-to-earnings ratio of -9.71 and a beta of 2.20.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). As a group, equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics has an average rating of “Hold” and an average price target of $8.63.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.